[1] Barker JL Jr, Garden AS, Ang KK, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head and neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys, 2004, 59(4):960-970.
[2] Hansen EK, Bucci MK, Quivey JM, et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2006, 64(2):355-362.
[3] Pouliot J, Bani-Hashemi A, Chen J, et al. Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys,2005, 61(2):238-241.
[4] Jani AB, Parikth SD, Vijayakumar S, et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology, 2005, 65(6):1157-1162.
[5] Kupelian PA, Potters aL, Khuntia D, et al. Radical prostatectomy,external beam radiotherapy <72GY, external beam radiotherapy 72GY, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys, 2004, 58(1):25-33.
[6] Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level Ⅳ. Int J Radiat Oncol Biol Phys, 2005, 62(3):706-713.
[7] Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer, early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys, 2002, 53(5):1111-1116.
[8] Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys, 2005, 63(3):765-771.
[9] Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy:analysis of toxicity and biochemical control. J Nucl Med, 2004, 45(8):1315-1322.
[10] Schettino CJ, Kramer EL, Noz ME, et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AIR, 2004,183(2):519-524.
[11] Jackson AS, Parker CC, Norman AR, et al, Tumor staging using magnetic resonance imaging in clinically localized prostate cancer:relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. Clin Oncol (R Coll Radiol),2005, 17(3):167-171.
[12] Pickett B, Ten Haken RK, Kurhanewicz J, et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radit Oncol Biol Phys,2004, 59(3):665-673.
[13] Ganswindt U, Paulsen F, Anastasiadis AG, et al. 70 Gy or more:which dose for which prostate cancer?. J Cancer Res Clin Oncol,2005, 131(7):407-419.
[14] Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys, 2003, 57(3):635-644.
[15] Pouliot J, Aubin M, Langen KM, et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic.portal imaging device. Int J Radiat Oncol Biol Phys,2003, 56(3):862-866.
[16] Niehoff P, Loch T, Numberg N, et al. Feasibility and preliminary outcome of salvage combined HDR braehytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Braehytherapy, 2005, 4(2):141-145.
[17] Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels Ⅰ and Ⅱ. Int J Radiat Oncol Biol Phys, 2003, 56(1):192-198.